IMMIX BIOPHARMA INC (IMMX)
Health Care · biotechnology · NASDAQ
Immix Biopharma is a clinical-stage biopharmaceutical company developing novel therapeutic candidates to address critical unmet needs in oncology and inflammatory disease treatment.
What IMMIX BIOPHARMA INC does
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for cancer and inflammatory diseases. The company utilizes proprietary technology platforms to develop product candidates intended to address significant unmet medical needs in oncology and immunology.
Themes: oncology, immunology, drug development
Fundamentals
- Price$9.29 as of 2026-10-08 close
- Market cap$665M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+265.7% 2025-10-08 close $2.54 → 2026-10-08 close $9.29
- P/En/a negative earnings
- ROE-31.4% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.48 as of 2026-09-02
- Last reported earningsn/a no earnings announcement (Form 8-K, Item 2.02) has been filed in our data yet
How IMMX compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How IMMIX BIOPHARMA INC looks technically
IMMIX BIOPHARMA INC (IMMX) is trading 1.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 336 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-08-03, breaking below its recent trading range. It is 38.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.70 | $11.70 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.16 | $9.16 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 44 calendar days ago — the swings before that are what the structure reading is measured on | 44 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 15.1. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 336 trading days ago — a "golden cross", a bullish long-term signal | 336 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with sellers in control | 32.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($8.96 to $12.90) — its "stochastic" reading is 8 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 8.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 24 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $15.10 | $15.10 |
|---|---|---|
| From the 52-week high | it is 38.5% below its 52-week high (its highest price of the past year) | -38.5% |
| Above the 52-week low | it is 365.7% above its 52-week low (its lowest price of the past year) | +365.7% |
| Below the 52-week high | it is 38.5% below its highest point of the past year | 38.5% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-03, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $15.10 (set on 2026-08-25) | $15.10 |
| Given back of the 52-week move | over the past year its closes ranged ($2.06 to $14.47), and it has given back roughly a third of its rise from last year’s low — 42% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.40 to $6.80. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 41.7% |
| From the all-time high | it is 38.5% below its all-time high | -38.5% |
| Nearest price level | it is trading 13.4% below a resistance level at $10.53 — a price it turned at twice since 2026-04-17, most recently on 2026-04-27. Since 2024-10-08 it has 9 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +13.4% |
| All-time low | its lowest closing price on record is $0.68 (set on 2022-11-10) | $0.68 |
| Above the all-time low | it is 1266.2% above its all-time low | +1,266% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8034 between its high and its low — about 8.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8034 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.90 and $13.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.90 – $11.22 – $13.54 |
| Typical daily range (% of price) | its price moves about 8.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.7% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (1.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 7.9% since the prior reading | +7.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.6% |
|---|---|---|
| Gap filled | a 2.7% gap up opened on 2026-09-17 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -8.29% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 30.9 percentage points (the stock lost 29.9% while the market gained 1.0%) | -30.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.4 percentage points (the stock lost 15.5% while the market gained 3.8%) | -19.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 9.3 percentage points (the stock gained 8.1% while the market gained 17.5%) | -9.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 250.8 percentage points (the stock gained 265.7% while the market gained 15.0%) | +250.8% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 19% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -19.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $9.70 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -4.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 22% below the average price paid since it last reported on 2026-08-07 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.97 — a volume-weighted average of daily closes over 44 sessions, not a true tick-by-tick VWAP. | -22.4% |
Price levels it has turned at before
IMMX last closed at $9.29 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.53 | Resistance | 13.4% above the last close | turned there twice · 2026-04-17 to 2026-04-27 |
| $8.00 | Support | 13.9% below the last close | turned there twice · 2026-03-27 to 2026-05-21 |
| $7.69 | Support | 17.2% below the last close | turned there twice · 2025-12-12 to 2026-06-08 |
| $2.50 | Support | 73.1% below the last close | turned there twice · 2025-01-06 to 2025-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $15.10.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 12 trading days, since 2026-09-23.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently RAISED · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$24.30 range $17.40 – $30.00; median $24.50
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMMX
- Consensus EPS estimate-$0.1886 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.0031 from -$0.1917, on 2026-09-04, 35-day window
- Readings revised upward17% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Need for substantial additional capital to fund operations and clinical development","Risks and uncertainties inherent in clinical trials, including potential for failure or unfavorable results","Dependence on third-party suppliers, manufacturers, and clinical research organizations"]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2025-12-10. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMMX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IMMX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 7,062,482
- Reported value $72,814,189
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IMMX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IMMX had 9,621,660 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IMMX had 13.4% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.75 days to cover at the same settlement.
- Reported short interest (shares) 9,621,660
- Short interest (% of shares outstanding) 13.4%
- Prior settlement (shares) 9,616,997
- Reported change 0.05%
- Days to cover (reported) 7.75
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
IMMIX BIOPHARMA INC is found in…
Frequently asked questions
What does IMMIX BIOPHARMA INC (IMMX) do?
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for cancer and inflammatory diseases. The company utilizes proprietary technology platforms to develop product candidates intended to address significant unmet medical needs in oncology and immunology.
What sector is IMMIX BIOPHARMA INC (IMMX) in?
IMMIX BIOPHARMA INC (IMMX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is IMMIX BIOPHARMA INC (IMMX) overbought or oversold right now?
IMMIX BIOPHARMA INC (IMMX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMMX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.